


Recovery expected in FY26

CMP: INR 471

Rating: Buy

Target Price: INR 582

Stock Info					
BSE		5	32400		
NSE		ı	BSOFT		
Bloomberg		BSC	DFT:IN		
Reuters		ВІ	RS.NS		
Sector	IT	Consul Sof	ting & tware		
Face Value (INR)			2		
Equity Capital (INR mn)			551.1		
Mkt Cap (INR mn)		1,3	31,473		
52w H/L (INR)		85	5/503		
Avg Yearly Vol (in 000')			1882		
Shareholding Pattern % (As on Dec, 2024)					
Promoters			40.82		
FII			11.00		
DII			24.63		
Public & Others			23.50		
Stock Performance (%)	1m	6m	12m		
Birlasoft	-8.5	10.6	38.8		



Nifty 50



-5.2

6.7

Abhishek Jain abhishek.jain@arihantcapital.com 022 67114851

Jyoti Singh jyoti.singh@arihantcapital.com 022 67114834 Birlasoft(BSFOT) reported consolidated revenue slightly below estimate; margin slightly up due to lower expenses and depreciation. However, PAT drops significantly due to higher finance costs and lower other income. Birlasoft reported Q3FY25 revenues of USD 160.8 mn down 1.5% QoQ/flat YoY versus (Our estimate of USD 161 Mn). Constant currency (CC) revenue growth is down 1.1% QoQ/ flat YoY. The company has reported consolidated revenue of INR 13,627 Mn, +1.5% YoY/ -0.4% QoQ in Q3FY25 slightly below (Our estimate of INR 13,789 Mn). Flat growth sequentially led by Manufacturing (+0.3% QoQ/-0.6% YoY) Energy & utility (+10.4% YoY/-2.8% QoQ) Life science (-3.4% QoQ/-15.1% YoY) while BFSI (+18.6% YoY/+2.8% QoQ). Consolidated EBIT stood at INR 1,422 Mn above (Our estimate of INR 1342 Mn) led by lower other expense & Depreciation. EBIT margin came at 10.4% above estimate of 9.73% down by 3 bps QoQ/down by 396bps. Consolidated PAT stood at INR 1,169 Mn, below (Our estimate of INR 1210 Mn) down 8.3% QoQ/down 27.4% YoY led by higher finance cost and lower other income. The order booking for Q3FY25, was at US \$64 mn in TCV (De-growth 28.1% QoQ/down 31.9% YoY) and renewals of \$ 162Mn. Active Client Count at 265in Q3FY25 (up from 261 in Q2FY25, with the number of \$5M+ clients rising from 24 in Q2FY25 to 27 in Q3FY25). DSO down by 5 Days to 53 Days in Q3FY25. LTM attrition up by 90bps QoQ at 12.7%; Headcount down by 453 to 12,125 in total. IT Utilization decline by 20bps QoQ; Offshore revenue 51% against 49.5% in Q2FY25.

Target to improve margin sequentially going forward: Birlasoft reported an EBITDA margin of 12% for Q3, nearly unchanged from Q2. Despite the impact of compensation hikes effective from October 1, 2024, the company managed to maintain margins, supported by favorable exchange rate movements and operational savings. Management remains committed to improving margins over time, with an aspiration to reach 15-16%, though the path may be gradual due to Q4 headwinds. Internal cost optimization processes and efficiency initiatives are in place to drive margin improvement quarter-over-quarter, though recent furloughs have posed challenges. Potential future headwinds include shifts in business mix favoring lower-margin segments, possible pricing pressures, and competitive pricing on new deals. However, the company remains focused on balancing margin expansion with strategic investments for growth.

Demand expected to pick up from FY26 onwards: The company sees early signs of improvement in BFSI and discretionary spending but remains cautious about a broad-based recovery. Demand is expected to gradually pick up through the year, though it may take a few quarters to reflect in deal inflows and revenues. The overall demand environment remains largely unchanged, with only limited recovery in financial services. Any meaningful improvement is likely to be more back-ended in the calendar year.

Valuations

Birlasoft reported a disappointing performance in Q3FY25, primarily due to high furloughs (150bps), especially within the life sciences and manufacturing sectors, which continued into January. Some furloughs are also extending into Q4, compounded by the effects of wage hikes. The company is struggling with both growth and deal wins. The weak exit rate and soft TCV outlook suggest a challenging FY26 as well. EPS estimates for FY26E/27E have been reduced by 4%/5%. The company aims for 15-16% EBITDA margins, but the path to achieving this may be slower due to ongoing challenges in Q4. We believe the stock is available at a cheaper level due to a 39% correction within a year amid uncertainty in the industry. However, there are early signs of demand recovery in sectors like financial services, and the EMU vertical is expected to lead growth over the next year. The manufacturing vertical is expected to remain soft for a couple more quarters. Our valuation, based on a PE of 24x FY27E EPS of ~INR 24.2, yields a target price of INR 582 per share. We upgrade our rating to a "Buy" from an Accumulate earlier.

Exhibit 2: Q3FY25 - Quarterly Performance (Consolidated)

Particulars (in INR Mn)	Q3FY25	Q2FY25	Q3FY24	Q-o-Q	Y-o-Y
Revenue (Mn USD)	160.80	163.30	161.30	-1.5%	-0.3%
Net Revenue	13,627	13,682	13,430	-0.4%	1.5%
Employee cost	8,329	8,296	7,934	0.4%	5.0%
Other Expenses	3,664	3,732	3,352	-1.8%	9.3%
EBITDA	1,634	1,653	2,143	-1.2%	-23.7%
EBITDA margin %	12.0%	12.1%	16.0%	-9bps	-396bps
Depreciation	213	222	211	-4.4%	1.0%
EBIT	1,422	1,431	1,932	-0.7%	-26.4%
EBIT margin %	10.4%	10.5%	14.4%	-3bps	-396bps
Other Income	208	334	282	-37.7%	-26.2%
Finance costs	69	68	60	2.4%	16.8%
PBT	1,560	1,697	2,154	-8.1%	-27.6%
Tax Expense	390	422	544	-7.4%	-28.2%
Effective tax rate %	25.0%	24.9%	25.2%	0.7%	-0.8%
PAT	1,169.39	1,275.07	1,610.58	-8.3%	-27.4%
MI & Associates	-	-	-		
Consolidated PAT	1,169.39	1,275.07	1,610.58	-8.3%	-27.4%
Exceptional item	-	-	-		
Reported PAT	1,169.39	1,275.07	1,610.58	-8.3%	-27.4%
PAT margin %	8.6%	9.3%	12.0%	-74bps	-341bps
EPS (INR)	4.2	4.6	5.8	-8.5%	-27.8%
Particulars (in INR Mn)	Q3FY25	Q2FY25	Q3FY24	Q-o-Q	Y-o-Y
Banking, Financial Services and Insurance	3,285	3,196	2,770	2.8%	18.6%
Manufacturing	5,472	5,458	5,504	0.3%	-0.6%
Energy and Utilities	2,144	2,205	1,942	-2.8%	10.4%
Life Sciences	2,727	2,824	3,213	-3.4%	-15.1%

Source: Arihant Research, Company Filings

Birlasoft - Q3FY25 Concall KTAs

- FY25 described as a "bad year", focus on returning to growth in FY26
- Q3 performance was impacted by higher-than-usual furloughs (150bps), particularly in the life sciences and manufacturing verticals, extending into January. Some furloughs are continuing into January, affecting Q4 as well. The demand environment remains largely unchanged from previous quarters
- Some early signs of demand improvement in areas like financial services, the overall demand environment remains challenging. The
 company expects gradual pickup as FY25 progresses.
- Clients expect demand to gradually improve through the year, though meaningful impact on deal inflows and revenues may take a
 few quarters.
- · Early signs of recovery in financial services and discretionary spending, but it's too soon to confirm a full demand turnaround.
- Expects good deal performance to continue in Q4 (TCV \$226 Mn in Q3)
- EBITDA margin was maintained at 12% despite wage hikes. Goal is to improve margins quarter-over-quarter. The company was able to largely offset the impact of the wage hike through exchange rate benefits from a strong dollar and some operational savings, wage increase that came into effect from October 1, 2024. Aspiration remains to reach 15-16% EBITDA margins, though the path to get there may be slower due to headwinds in Q4.
- Focusing on improving predictability, expanding its client base, and investing in capabilities like AI and Gen AI to drive future growth.
- Some project ramp-downs seen in healthcare and manufacturing in Q3 may have near-term revenue impact.
- Deal pipeline remains healthy. No pricing pressure from clients yet, but new deal competition is intense.
- Segments: Hired new leaders for medical devices and pharma businesses. Financial services and EMU verticals expected to lead growth over next year. Manufacturing vertical expected to remain soft for a couple more quarters.
- Cash balance increased to \$240 mn, up 18.3% YoY.
- Company is working to add new logos across verticals.
- ERP business expected to turn around in the medium term.
- Top 6-10 accounts saw sharp sequential decline of 5%. Company focusing on improving mining of top accounts.
- No immediate plans to return cash to shareholders, conserving for potential opportunities. Continue to give the dividend to shareholder
- Confident about closing a reasonable-sized deal with a new logo in Europe.
- Infrastructure business outperforming applications business may impact margins.
- Expects any demand improvement to be more back-ended in the calendar year, not in the next two quarters.
- Won a strategically significant "marquee deal" with a new client in Europe, though not large in size.

2

Exhibit 3: Key Operating Metrics

Exhibit 3: Key Operating Metrics	0051100	0.451/00	0.4 57/0.4	0051104	0051104	0.453/0.4	0451405	00=1/0=	005/05
USD Revenues (\$ Mn)	Q3FY23 148.4	Q4FY23 149.10	Q1FY24 153.60	Q2FY24 158.30	Q3FY24 161.30	Q4FY24 163.90	Q1FY25 159.10	Q2FY25 163.30	Q3FY25 160.80
QoQ growth %	-0.3%	0.5%	3.0%	3.1%	1.9%	1.6%	-2.9%	2.6%	-1.5%
USD/INR	82.3	82.26	82.2	83.2	84.2	83.12	83.41	83.78	84.73
Client Geography	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Americas	124.2	127.2	131.8	135.8	138.2	141.8	133.6	142.6	141.2
% contribution	83.7%	85.3%	85.8%	85.8%	85.7%	86.5%	84.0%	87.3%	87.8%
qoq	-0.7%	2.4%	3.6%	3.1%	1.8%	2.6%	-5.7%	6.7%	-1.0%
yoy	4.5%	5.7%	4.5%	8.5%	11.3%	11.5%	1.4%	5.0%	2.1%
Rest of the World	24.2	8.5	9.2	22.5	23.1	22.1	25.5	20.7	19.6
% contribution	16.3%	5.7%	6.0%	14.2%	14.3%	13.5%	16.0%	12.7%	12.2%
qoq	158.0%	-64.9%	8.4%	143.9%	2.6%	-4.1%	15.0%	-18.5%	-5.4%
уоу	163.6%	-12.0%	5.1%	139.8%	-4.6%	160.4%	176.2%	-7.7%	-14.9%
Revenue by Industry Verticals	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
BFSI	29.8	30.6	31.8	33.4	33.2	34.7	37.5	38.0	38.8
% contribution	20.1%	20.5%	20.7%	21.1%	20.6%	21.2%	23.6%	23.3%	24.1%
qoq	5.0%	2.5%	4.0%	5.1%	-0.5%	4.6%	8.1%	1.3%	1.8%
yoy	17.5%	21.4%	20.2%	17.5%	11.4%	13.7%	18.1%	13.9%	16.6%
Canana O Hailiaina	20.5	22.5	22.5	2.1	22.1	21.5	25.4	25.5	25.2
Energy & Utilities % contribution	20.6 13.9%	22.2 14.9%	22.0 14.3%	21.7 13.7%	23.4 14.5%	24.3 14.8%	25.1 15.8%	26.3 16.1%	25.2 15.7%
qoq	-1.7%	7.7%	-1.1%	-1.3%	7.8%	3.7%	3.6%	4.6%	-4.0%
yoy	-2.8%	0.5%	3.4%	3.4%	13.4%	9.2%	14.4%	21.2%	7.9%
	,	2.074	2,0						
Lifesciences	29.5	26.2	37.5	38.0	38.6	36.2	34.0	33.6	32.2
% contribution	19.9%	17.6%	24.4%	24.0%	23.9%	22.1%	21.4%	20.6%	20.0%
qoq	1.3%	-11.1%	42.8%	1.4%	1.5%	-6.0%	-6.0%	-1.2%	-4.4%
yoy	-7.7%	-17.0%	19.0%	30.3%	30.5%	38.0%	-9.2%	-11.5%	-16.6%
Manufacturing	68.4	70.2	62.5	65.1	66.3	68.7	62.4	65.3	64.5
% contribution	46.10%	47.10%	40.70%	41.10%	41.10%	41.90%	39.20%	40.00%	40.10%
qoq	-2.6%	2.7%	-11.0%	4.1%	1.9%	3.6%	-9.2%	4.7%	-1.3%
уоу	5.5%	4.1%	-9.9%	-7.4%	-3.1%	-2.2%	-0.2%	0.4%	-2.7%
Revenue by Service Offerings	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Digital & Cloud % contribution	45.6 30.70%	47.3	83.3 54.20%	87.9	89.4	87.7 53.50%	83.8	89.3	91.5
ERP	30.70%	31.70% 41.7	54.20% 44.0	55.50% 43.7	55.40% 44.1	47.8	52.70% 46.6	54.70% 50.6	56.90% 47.9
% contribution	31.80%	32.80%	33.40%	32.20%	31.90%	33.70%	34.90%	35.50%	33.90%
Infrastructure	13.8	11.3	12.9	12.5	13.7	14.4	19.7	16.0	14.6
% contribution	9.30%	7.60%	8.40%	7.90%	8.50%	8.80%	12.40%	9.80%	9.10%
Revenue by Service Offerings	025722	045733	Q1FY24	O2FV24	O25V24	O4FV24	015735	Q2FY25	02EV2E
Revenues by Contract Type Time & Material	Q3FY23 39.20%	Q4FY23 38.30%	38.50%	Q2FY24 39.10%	Q3FY24 37.30%	Q4FY24 38.40%	Q1FY25 37.30%	36.00%	Q3FY25 35.20%
Fixed Price, Fixed Monthly	60.8%	61.7%	61.5%	60.9%	62.7%	61.6%	62.7%	64.0%	64.8%
		, 9							
Revenues Mix									
Onsite	48.9%	48.6%	49.0%	48.8%	45.8%	47.8%	43.5%	50.5%	49.0%
qoq	1.6%	-0.1%	3.9%	2.6%	-4.4%	6.0%	-11.7%	19.2%	-4.5%
yoy									
Offshore	51.1%	51.4%	51.0%	51.2%	54.2%	52.2%	56.5%	49.5%	51.0%
qoq	-2.0%	1.1%	2.2%	3.5%	7.9%	-2.1%	5.1%	-10.1%	1.5%
yoy									
Deal Wins - New	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
New Total Contract Value (TCV) - in \$ Mn	102	114	80	167	94	107	94	89	64
Total Hoodsoupt	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Total Headcount Addition/Deletion	12530 -228	12,193 -337	12235 42	12322 87	12,356 34	12,595 239	12,865 270	12,578 -287	12,125 -453
Technical	11386	11,043	11061	11130	11,169	11,433	11,597	11,417	11,000
Addition/Deletion	-182	-343	18	69	39	264	164	-180	-417
Sales & Support	1144	1,150	1174	1192	1187	1162	1268	1161	1125
Addition/Deletion	-46	6	24	18	-5	-25	106	-107	-36
Women Employees	2943	2,852	2863	2906	2892	2968	3048	2972	2891
Attrition (LTM)	25.50%	22.10%	18.80%	15.00%	12.60%	12.40%	11.60%	11.80%	12.70%
Utilization Source: Arihant Research, Company Filings	84.00%	84.80%	84.90%	86.50%	87.10%	86.30%	81.70%	82.00%	81.80%

	Profit & Loss Accou	nt		
Y/E Mar	FY24	FY25E	FY26E	FY27
Revenue in USD mn	637	647	675	70
Growth (%)	7.09%	1.5%	4.3%	4.19
Net sales	52,781	54,421	57,173	59,05
Growth (%)	10.08%		5.1%	3.39
Consumption of materials	-	-	_	
Staff Expenses	30,483	32,674	34,458	34,55
Other operating expenses	13,936		15,437	16,38
Total Expenditure	44,419		49,895	50,94
EBITDA	8,362		7,278	<u> </u>
EBITDA Margin	15.84%	· · · · · · · · · · · · · · · · · · ·	12.73%	13.739
Depreciation	850		1,783	1,91
Operating profit	7,512	,		6,19
Other income	1,035	•	1,410	1,50
EBIT	8,547	,	,	
EBIT Margin	16.19%	•	12.08%	
Interest	199		264	26
	199	249	204	20
Exceptional items Profit before tax		- -	-	7 40
	8,348	·	6,641	-
Tax	2,110		1,660	
Share in profit of associate cos	25.3%	24.7%	25.0%	25.09
Minority interest		-	-	
Reported net profit	6,238	4,612	4,981	5,57
EO Items	-	-	-	
Adjusted net profit	6,238		4,986	-
Share O/s mn	278		230	23
Adj. EPS INR	22.5	17.9	21.7	24.
Balance Sheet				
Y/E Mar	FY24	FY25E	FY26E	FY27
APPLICATION OF FUNDS :		-	-	
Non Current Assets	8,723	9,235	10,164	11,29
Fixed Assets	1,142	1,612	2,365	3,29
Capital work in progress	116	-	-	
Goodwill & other Intangibles	4,957	4,957	4,957	4,95
Noncurrent investment	-	-	-	
Deferred tax assets	1,283	1,391	1,507	1,63
Long term loans and advances	1 224	1 276	1 220	1.40
Other non-current assets Current Assets	1,224 27,674		1,336 40.123	1,40 43,77
Current investment	10,336		10,336	
Inventories	10,330	10,550	10,550	10,55
Sundry debtors	10,365	8,200	8,615	8,89
Cash and bank	4,249		18,144	
Short loans and advances	-	-	<u> </u>	,
Others current assets	2,723	2,884	3,028	3,17
Total Assets	39,256	46,102	50,288	55,06
SOURCES OF FUNDS:				
Share Capital	551.1		551.1	
Reserves	29,889			43,26
Total Shareholders Funds	30,440	36,249	39,735	43,81
Minority interest		-	-	4.50
Non-Current Liabilities	1,290	1,373	1,463	1,56
Long term borrowings	-	-	-	
Deferred tax liability Other long term liabilities	578	589	601	61
Long-term provisions	712			
Current Liabilities	7,458			
Short term borrowings	7,436	-	3,030	3,00
Trade payables	2,805	3,429	3,603	3,72
Other current liabilities	4,022			
Short term provisions	631			
Total Equity & Liabilities	39,256			

Source: Arihant Research, Company Filings

Key Financials

Cash Flow Statement				
Y/E Mar	FY24	FY25E	FY26E	FY27E
PBT	8,348	6,124	6,641	7,432
Non-cash adjustments	15	768	637	678
Changes in working capital	(285)	3,074	103	220
Tax Paid	(1,815)	(1,596)	(1,750)	(1,955)
Cashflow from operations	6,263	8,370	5,631	6,375
Capital expenditure	(544)	(1,963)	(2,536)	(2,849)
Change in investments	(5,428)	(1,505)	(2,330)	(2,043)
Other investing cashflow	1,057	1,038	1,350	1,430
Cashflow from investing	(4,915)	(925)	(1,186)	(1,419)
	(4,313)	(925)	(1,100)	(1,415)
Issue of equity	4	-	-	-
Issue/repay debt	(400)	(2.40)	(2.6.1)	(2.50)
Interest Paid	(199)	(249)	(264)	(260)
Increase / (Decrease) in Loan Funds				
Dividends paid	(1,663)	(1,746)	(1,495)	(1,495)
Other financing cashflow	(84)	12	12	12
Cashflow from financing	(1,946)	(1,983)	(1,747)	(1,743)
Change in cash & cash eq	(598)	5,463	2,698	3,213
Opening cash & cash eq	4,249	15,447	18,144	21,357
Closing cash & cash eq	3,651	20,909	20,842	24,570
Closing cash & Bank Bal.	3,975	21,233	21,166	24,894
Free cash flow to firm	5,719	6.407	3,095	3,526
	3,7.23	0, 107	5,035	3,320
Ratios				
Y/E Mar	FY24	FY25E	FY26E	FY27E
PER SHARE				
	20.5	47.0	24 7	
EPS INR	22.5	17.9	21.7	24.2
CEPS INR	25.5	25.0	25.2	26.1
Book Value INR	109.7	157.6	172.8	190.5
VALUATION				
EV / Net Sales	2.4	1.7	1.6	1.5
EV / EBITDA	15.1	13.5	12.4	10.7
P / E Ratio	21.0	26.4	21.7	19.4
P / BV Ratio	4.3	3.0	2.7	2.5
GROWTH YOY%				
Sales Growth	10.1	(4.8)	(2.4)	(3.6)
EBITDA Growth	24.5	(23.9)	(1.9)	4.0
Net Profit Growth	29.3	(31.8)	0.3	4.5
Gross Fixed Asset Growth	17.5	15.3	14.0	12.7
PROFITABILITY				
Gross Profit/ Net sales ((%)	42.2	40.0	39.7	41.5
EBITDA / Net Sales (%)	15.8	12.7	12.7	13.7
EBIT / Net sales(%)	14.2	9.7	9.6	10.5
NPM / Total income (%)	11.8	8.5	8.7	9.4
ROE (%)	20.5	12.7	12.5	12.7
ROCE (%)	26.9	16.9	16.8	17.0
Tax / PBT %	25.3	24.7	25.0	25.0
TURNOVER				
Net Woking Cycle	52	37	41	46
Debtors Velocity (Days)	72	60	64	69
Inventory (Days)	-	-	-	
Creditors Velocity (Days)	19	23	23	23
Current Ratio	3.7	4.3	4.4	4.5
Quick Ratio	3.7	4.3	4.4	4.5
LIQUIDITY				
Gross Asset Ratio	6.5	5.6	5.1	4.7
Total Asset Ratio	1.3	1.2	1.1	1.1
Net Debt-Equity Ratio	(0.1)	(0.4)	(0.5)	(0.5)
Interest Coverage	42.9	25.6	26.2	29.6

Disclaimer: This disclosure statement is provided in compliance with the SEBI Research Analyst Regulations, 2014. Arihant Capital Markets Limited (ACML) is a registered stockbroker, merchant banker, and research analyst under SEBI, and is also a Point of Presence with the Pension Fund Regulatory and Development Authority (PFRDA). ACML is registered with SEBI with Research Analyst Registration Number INH000002764, Stockbroker Registration Number INZ000180939, and is a Trading Member with NSE, BSE, MCX, NCDEX, and a Depository Participant with CDSL and NSDL.

ACML and its associates may have business relationships, including investment banking, with companies covered by its Investment Research Department. The analysts of ACML, and their associates, are prohibited from holding a financial interest in securities or derivatives of companies they cover, though they may hold stock in the companies they analyze. The recommendations provided by ACML's research team are based on technical and derivative analysis and may differ from fundamental research reports.

ACML confirms that neither it nor its associates have a financial interest or material conflict concerning the companies covered in the research report at the time of publication. Furthermore, ACML, its analysts, and their relatives have no ownership greater than 1% in the subject companies as of the month prior to publication. ACML guarantees that the compensation for its research analysts is not influenced by specific securities or transactions.

ACML affirms that neither the analyst nor the company has served as an officer, director, employee, or engaged in market-making activities for any of the subject companies. Additionally, the research report does not reflect any conflict of interest and is not influenced by specific recommendations made. Neither ACML nor its analysts have received compensation for investment banking or brokerage services from the subject companies in the last 12 months.

The views expressed in this report are those of the analysts and are independent of the proprietary trading desk of ACML, which operates separately to maintain an unbiased stance. Analysts comply with SEBI Regulations when offering recommendations or opinions through public media. The report is intended for informational purposes only and is not an offer or solicitation for the purchase or sale of securities.

This report, which is confidential, may not be reproduced or shared without written consent from ACML. It is based on publicly available data believed to be reliable but has not been independently verified, and no guarantees are made about its accuracy. All opinions and information contained in the report are subject to change without notice.

ACML disclaims liability for any losses resulting from reliance on this report. The report does not constitute an offer to buy or sell securities, and ACML is not responsible for the risks involved in investments. ACML and its affiliates may have positions in the securities discussed or hold other financial interests in them.

The distribution of this report in certain jurisdictions may be restricted by law, and the report is not intended for distribution where it would violate local laws. Investors are advised to consider their financial position, risk tolerance, and investment objectives before engaging in transactions, particularly in high-risk financial products such as derivatives.

ACML reserves the right to modify this disclosure statement without prior notice. The report has been prepared using publicly available information and internally developed data, though ACML does not guarantee its completeness or accuracy. Historical price data for securities can be accessed via official exchanges like NSE or BSE.

ACML and its affiliates may conduct proprietary transactions or investment banking services for the companies mentioned in this report. In compliance with SEBI regulations, ACML maintains comprehensive records of research reports, recommendations, and the rationale for those recommendations, which are preserved for at least five years. An annual compliance audit is conducted by a member of the ICAI or ICSI to ensure adherence to applicable regulations.

This report is issued in accordance with applicable SEBI regulations and does not guarantee future performance or returns.

Arihant Research Desk

Email: instresearch@arihantcapital.com

Tel. : 022-42254800

Head Office	Registered Office
#1011, Solitaire Corporate Park	
Building No. 10, 1 st Floor	6 Lad Colony,
Andheri Ghatkopar Link Road	Y.N. Road,
Chakala, Andheri (E)	Indore - 452003, (M.P.)
Mumbai – 400093	Fax: (91-731) 4217101
Tel: (91-22) 42254800	
Fax: (91-22) 42254880	

Stock Rating Scale	Absolute Return
BUY	>20%
ACCUMULATE	12% to 20%
HOLD	5% to 12%
NEUTRAL	-5% to 5%
REDUCE	-5% to -12%
SELL	<-12%

Research Analyst Registration No.	Contact	Website	Email Id
INH000002764	SMS: 'Arihant' to 56677	www.arihantcapital.com	research@arihantcapital.com

Arihant Capital Markets Ltd. 1011, Solitaire Corporate park, Building No. 10, 1st Floor, Andheri Ghatkopar Link Road, Chakala, Andheri (E) Tel. 022-42254800Fax. 022-42254880